論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
掲載誌名	正式名：Alimentary pharmacology & therapeutics 略　 称：Aliment Pharmacol Ther ISSNコード：02692813/13652036
掲載区分	国外
巻・号・頁	60(10),pp.1361-1373
著者・共著者	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for, HCC (RELPEC) Study Group, and, HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan).
発行年月	2024/11
DOI	10.1111/apt.18237
PMID	39233317